OBJECTIVE: To investigate the risk of Alzheimer disease (AD) in first-degree relatives of patients with Parkinson disease (PD) compared with first-degree relatives of controls. DESIGN: Case-control study, family history method, and reconstructed cohort approach. METHODS: Probands with PD without dementia and control probands, matched by age strata, sex, and ethnicity, were examined in person and enrolled without knowledge of family history of PD and other neurological disorders. Disease status in first-degree relatives of probands with PD and control probands was ascertained through a structured family history interview administered to the proband and a second informant (self-report or another informant). Cox proportional hazards models with double-censoring techniques for missing information on age of onset of AD were used to analyze the risk of AD in first-degree relatives of patients with PD compared with first-degree relatives of controls. RESULTS: Four hundred eighty-seven probands with PD and 409 control probands provided family history information on 4819 first-degree relatives older than 30 years (2534 relatives of probands with PD and 2285 relatives of control probands). One hundred thirteen first-degree relatives (2.3%; 61 relatives [2.4%] of patients with PD and 52 relatives [2.3%] of controls) were diagnosed with AD. The risk of AD was not increased in relatives of patients with PD compared with relatives of controls (hazard ratio, 1.1; 95% confidence interval, 0.7-1.6; P =.65). Similarly, no significantly increased risk of AD was observed when comparing relatives of patients with early-onset (< or =50 years) and late-onset (>50 years) PD with relatives of controls. CONCLUSION: The lack of familial aggregation of PD and AD does not support the hypothesis of major shared genetic contributions to the etiology of the 2 most common neurodegenerative disorders.
OBJECTIVE: To investigate the risk of Alzheimer disease (AD) in first-degree relatives of patients with Parkinson disease (PD) compared with first-degree relatives of controls. DESIGN: Case-control study, family history method, and reconstructed cohort approach. METHODS: Probands with PD without dementia and control probands, matched by age strata, sex, and ethnicity, were examined in person and enrolled without knowledge of family history of PD and other neurological disorders. Disease status in first-degree relatives of probands with PD and control probands was ascertained through a structured family history interview administered to the proband and a second informant (self-report or another informant). Cox proportional hazards models with double-censoring techniques for missing information on age of onset of AD were used to analyze the risk of AD in first-degree relatives of patients with PD compared with first-degree relatives of controls. RESULTS: Four hundred eighty-seven probands with PD and 409 control probands provided family history information on 4819 first-degree relatives older than 30 years (2534 relatives of probands with PD and 2285 relatives of control probands). One hundred thirteen first-degree relatives (2.3%; 61 relatives [2.4%] of patients with PD and 52 relatives [2.3%] of controls) were diagnosed with AD. The risk of AD was not increased in relatives of patients with PD compared with relatives of controls (hazard ratio, 1.1; 95% confidence interval, 0.7-1.6; P =.65). Similarly, no significantly increased risk of AD was observed when comparing relatives of patients with early-onset (< or =50 years) and late-onset (>50 years) PD with relatives of controls. CONCLUSION: The lack of familial aggregation of PD and AD does not support the hypothesis of major shared genetic contributions to the etiology of the 2 most common neurodegenerative disorders.
Authors: Gail A Kang; Jeff M Bronstein; Donna L Masterman; Matthew Redelings; Jarrod A Crum; Beate Ritz Journal: Mov Disord Date: 2005-09 Impact factor: 10.338
Authors: Michael Y Shino; Valerie McGuire; Stephen K Van Den Eeden; Caroline M Tanner; Rita Popat; Amethyst Leimpeter; Allan L Bernstein; Lorene M Nelson Journal: Mov Disord Date: 2010-11-15 Impact factor: 10.338
Authors: Karen S Marder; Ming X Tang; Helen Mejia-Santana; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Andrew D Siderowf; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Barbara M Ross; Lucien J Cote; Steven Frucht; Blair Ford; Roy N Alcalay; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Gregory D Neils; Miguel Verbitsky; Sergey Kisselev; Elise Caccappolo; Ruth Ottman; Lorraine N Clark Journal: Arch Neurol Date: 2010-06
Authors: Yuanjia Wang; Lorraine N Clark; Elan D Louis; Helen Mejia-Santana; Juliette Harris; Lucien J Cote; Cheryl Waters; Howard Andrews; Blair Ford; Steven Frucht; Stanley Fahn; Ruth Ottman; Daniel Rabinowitz; Karen Marder Journal: Arch Neurol Date: 2008-04
Authors: Adina L Feldman; Karin Wirdefeldt; Anna L V Johansson; Margaret Gatz; Nancy L Pedersen Journal: Eur J Epidemiol Date: 2013-11-19 Impact factor: 8.082
Authors: Ami R Rosen; N Kyle Steenland; John Hanfelt; Stewart A Factor; James J Lah; Allan I Levey Journal: Neurogenetics Date: 2007-09-06 Impact factor: 2.660
Authors: Valentina Moskvina; Denise Harold; GianCarlo Russo; Alexey Vedernikov; Manu Sharma; Mohamed Saad; Peter Holmans; Jose M Bras; Francesco Bettella; Margaux F Keller; Nayia Nicolaou; Javier Simón-Sánchez; J Raphael Gibbs; Claudia Schulte; Alexandra Durr; Rita Guerreiro; Dena Hernandez; Alexis Brice; Hreinn Stefánsson; Kari Majamaa; Thomas Gasser; Peter Heutink; Nick Wood; Maria Martinez; Andrew B Singleton; Michael A Nalls; John Hardy; Michael J Owen; Michael C O'Donovan; Julie Williams; Huw R Morris; Nigel M Williams Journal: JAMA Neurol Date: 2013-10 Impact factor: 18.302